Clinical trials: Adult Hepatocellular Carcinoma
HepatoCellular Carcinoma
CHARM Hepatocellular Carcinoma MEA Study
Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the third reason for cancer-related death worldwide.
- Trial name
- NCT07650773
- Where
- 17 sites in Egypt, Kuwait and 5 more
- Volunteers
- 4,000 people
- Sponsor
- AstraZeneca
Liver Cancer
Vaccine Therapy in Treating Patients With Liver Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have liver cancer.
- Trial name
- NCT00005629
- Testing
- AFP gene hepatocellular carcinoma vaccine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Liver Cancer
Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NRR (NCT00483405)
- Testing
- cetuximab, capecitabine, oxaliplatin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer, Colorectal Cancer
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00553683
- Testing
- cyclophosphamide, poly ICLC, hepatic artery embolization
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
This phase II trial is studying how well lapatinib works in treating patients with locally advanced or metastatic biliary tract or liver cancer that cannot be removed by surgery.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00101036
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer, Adult
RAdiation SEgmentectomy With REsin Microspheres (RASEREM) Study
Radiation segmentectomy (RS) refers to selective infusion of Y-90 microspheres to the tumor bearing hepatic segment of hepatic artery. Majority of the data on RS is based on the Glass microspheres experience.
- Trial name
- RASEREM (NCT07345247)
- Where
- 20 sites in Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Ankara University
Esophageal Cancer, Extrahepatic Bile Duct Cancer
Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gastric Cancer, Head and Neck Cancer
- Trial name
- NCT00021047
- Testing
- capecitabine, carboplatin, epirubicin hydrochloride
- Where
- 3 sites in United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
IMC-A12 in Treating Patients With Advanced Liver Cancer
This phase II trial is studying how well IMC-A12 works in treating patients with advanced liver cancer. Monoclonal antibodies, such as IMC-A12, can block tumor growth in different ways.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00639509
- Testing
- cixutumumab, computed tomography, contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer (Locally Advanced or Metastatic), Liver Cancer Adult
Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)
This clinical trial will test whether a short infusion of a drug called angiotensin II (AT-II) can make a liver cancer treatment work better.
- Trial name
- RADIANT (NCT07312292)
- Testing
- Angiotensin II (Giapreza®), Yttrium-90 radioembolization
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Niek Wijnen
Solid Tumor (Excluding CNS), Hepatocellular Carcinoma
Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors
This Phase 1, open-label, non-randomized study will enroll adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors expressing glypican-3 (GPC3) to examine the safety, feasibility, and…
- Conditions
- Solid Tumor (Excluding CNS), Hepatocellular Carcinoma, Liver Cell Carcinoma, Liposarcoma
- Trial name
- INTERCEPT (NCT07224568)
- Testing
- SC-CAR.GPC3xIL15.21 CAR T cells
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Seattle Children's Hospital
Liver Cancer, Adult
The Diagnostic Efficacy and Lesion Detection Advantages of 18F-FDG PET/Contrast-enhanced MRI in Malignant Liver Lesions
Liver disease, a major global health burden, ranges from mild dysfunction to severe conditions like cirrhosis and hepatocellular carcinoma (HCC), the fifth most common cancer.
- Trial name
- NCT07055048
- Volunteers
- 60 people
- Sponsor
- Shanghai East Hospital
Liver Cancer, Adult, Metastatic Liver Cancers
Mts105 for Advanced Hepatocellular Carcinoma
This is the first-in-human trial of MTS105 (mRNA-LNP). The goal of this clinical trial is to evaluate the safety, tolerability of intravenous injection of MTS105 in advanced hepatocellular carcinoma.
- Conditions
- Liver Cancer, Adult, Metastatic Liver Cancers, HCC - Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC)
- Trial name
- MTS105 for HCC (NCT06689540)
- Testing
- MTS105
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Shen Lin
Adult Primary Hepatocellular Carcinoma, Localized Resectable Adult Primary Liver Cancer
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and effective treatment option for preventing liver cancer in high risk patients following liver transplantation.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT01624285
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- 21 sites in United States
- Volunteers
- 73 people
- Sponsor
- Jonsson Comprehensive Cancer Center